These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16513894)

  • 1. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
    Kane JM
    J Clin Psychiatry; 2006 May; 67(5):831-2. PubMed ID: 16841634
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone and clozapine for treatment-resistant schizophrenia.
    Meltzer HY
    Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484
    [No Abstract]   [Full Text] [Related]  

  • 5. The CATIE study.
    Basil B; Mathews M; Adetunji B; Budur K
    Am J Psychiatry; 2006 Mar; 163(3):555; author reply 555-6. PubMed ID: 16513895
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials design lessons from the CATIE study.
    Kraemer HC; Glick ID; Klein DF
    Am J Psychiatry; 2009 Nov; 166(11):1222-8. PubMed ID: 19797435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 8. First- vs second-generation antipsychotic drugs in schizophrenia.
    Andrade C; Kharawala S
    Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 10. CUtLASS confirms CATIE.
    Mintz J; Kopelowicz A
    Arch Gen Psychiatry; 2007 Aug; 64(8):978; author reply 979-80. PubMed ID: 17679644
    [No Abstract]   [Full Text] [Related]  

  • 11. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of antipsychotic drugs.
    Osser DN; Akhter A
    Am J Psychiatry; 2003 Mar; 160(3):590; author reply 592-3. PubMed ID: 12611853
    [No Abstract]   [Full Text] [Related]  

  • 13. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 15. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 16. [Priority for atypical antipsychotic drugs? Current studies clarify the issues].
    Dose M
    Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252
    [No Abstract]   [Full Text] [Related]  

  • 17. Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.
    Stensland MD; Ascher-Svanum H; Lawson AH; Conley RR
    J Clin Psychiatry; 2009 Aug; 70(8):1189-90; author reply 1190-91. PubMed ID: 19758530
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation versus conventional antipsychotics.
    Geddes J; Harrison P; Freemantle N
    Lancet; 2003 Aug; 362(9381):404; author reply 404-5. PubMed ID: 12907021
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.